Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer

Background: Aminolevulinic acid (ALA)-based photodynamic therapy (PDT) provides selective uptake and conversion of ALA into protoporphyrin IX (PpIX) in actinic keratosis and squamous cell carcinoma, yet large response variations in effect are common between individuals. The aim of this study was to...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:British journal of cancer Ročník 115; číslo 7; s. 805 - 813
Hlavní autoři: de Souza, Ana Luiza Ribeiro, Marra, Kayla, Gunn, Jason, Samkoe, Kimberley S, Kanick, Stephen Chad, Davis, Scott C, Chapman, M Shane, Maytin, Edward V, Hasan, Tayyaba, Pogue, Brian W
Médium: Journal Article
Jazyk:angličtina
Vydáno: London Nature Publishing Group UK 27.09.2016
Nature Publishing Group
Témata:
631/154/436
692/699/67/1059
692/699/67/1813
Acids
Aminolevulinic Acid - therapeutic use
Animals
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cancer therapies
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - pathology
Cell Line, Tumor
Deferoxamine - pharmacology
Deferoxamine - therapeutic use
Dose Fractionation
Dose-Response Relationship, Radiation
Drug Resistance
Epidemiology
FDA approval
Female
Fractionation
Heme - biosynthesis
Humans
Lasers, Semiconductor
Light
Lighting - instrumentation
Lighting - methods
Medical research
Mice
Mice, Nude
Molecular Medicine
Oncology
Photochemotherapy - methods
Photodynamic therapy
Photosensitizing Agents - pharmacokinetics
Photosensitizing Agents - therapeutic use
Protoporphyrins - pharmacokinetics
Protoporphyrins - therapeutic use
Random Allocation
Siderophores - pharmacology
Siderophores - therapeutic use
Skin cancer
Skin Neoplasms - drug therapy
Skin Neoplasms - pathology
Translational Therapeutics
Tumor Burden
Xenograft Model Antitumor Assays
Brazil
United States > US
aminolevulinic acid
fractionation
dose
protoporphyrin IX
photodynamic
iron chelator
ISSN:0007-0920, 1532-1827, 1532-1827
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Background: Aminolevulinic acid (ALA)-based photodynamic therapy (PDT) provides selective uptake and conversion of ALA into protoporphyrin IX (PpIX) in actinic keratosis and squamous cell carcinoma, yet large response variations in effect are common between individuals. The aim of this study was to compare pre-treatment strategies that increase the therapeutic effect, including fractionated light delivery during PDT (fPDT) and use of iron chelator desferrioxamine (DFO), separately and combined. Methods: Optical measurements of fluorescence were used to quantify PpIX produced, and the total amount of PpIX photobleached as an implicit measure of the photodynamic dose. In addition, measurements of white light reflectance were used to quantify changes in vascular physiology throughout the PDT treatment. Results: fPDT produced both a replenishment of PpIX and vascular re-oxygenation during a 2 h dark interval between the first and second PDT light fractions. The absolute photodynamic dose was increased 57% by fPDT, DFO and their combination, as compared with PDT group (from 0.7 to 1.1). Despite that light fractionation increased oedema and scab formation during the week after treatment, no significant difference in long-term survival has been observed between treatment groups. However, outcomes stratified on the basis of measured photodynamic dose showed a significant difference in long-term survival. Conclusions: The assessment of implicit photodynamic dose was a more significant predictor of efficacy for ALA-PDT skin cancer treatments than prescription of an enhanced treatment strategy, likely because of high individual variation in response between subjects.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0007-0920
1532-1827
1532-1827
DOI:10.1038/bjc.2016.267